Major Investors & Financial Advisor Resell 9.6M Shares, Company Receives No Proceeds Amidst 'Going Concern' Warning
LABT is trading near its 52-week low of $1.92 (3.1% above the low) on light trading volume (0.1× avg).
Summary
Lakewood-Amedex Biotherapeutics Inc. filed a final prospectus for the resale of 9.6 million shares by major investors and its financial advisor, which could result in over 67% dilution for existing shareholders, with no proceeds going to the company, amidst a 'going concern' warning.
Key Events · Financing and Capital Events · LABT
-
Massive Potential Dilution
A final prospectus was filed for the resale of 9,647,726 shares of common stock, representing approximately 67.37% of the current outstanding shares.
-
No Proceeds to Company
The company will not receive any funds from the sale of these shares, despite facing a 'going concern' warning from its auditors.
-
Major Selling Stockholders
The shares are being resold by Shakawe Capital LLC (a major investor from a Series C Preferred Stock financing) and Dawson James Securities, Inc. (the company's financial advisor).
-
Financial Distress Confirmed
The company's financial statements include an explanatory paragraph from auditors expressing 'substantial doubt about our ability to continue as a going concern'.
Analysis · LABT · Life Sciences
This final prospectus enables major investors and the company's financial advisor to resell 9.6 million shares, representing a massive 67% potential dilution for existing shareholders. The company will receive no proceeds from these sales, which is a critical negative given the explicit 'going concern' warning from auditors. The fact that key stakeholders are selling shares, some convertible at a deep discount to current market prices, signals severe financial distress and a lack of confidence, placing significant downward pressure on the stock, which is already trading near its 52-week low.
At the time of this filing, LABT was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5M. The 52-week trading range was $1.92 to $9.82. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.